FLT3 and acute myeloid leukemia: The phase III ADMIRAL trial showed improved overall survival with the gilteritinib vs salvage chemotherapy in patients with Flt3-mutated acute myeloid leukemia (13), making gilteritinib a routine therapy for adult AML patients who have relapsed or refractory diseases with a Flt3 mutation.